Vita Coco Company, Inc. SEC Filings

The Vita Coco Company, Inc. (COCO) furnished an update on its operations by announcing financial results for the three months ended September 30, 2025. The results were disclosed through a press release furnished as Exhibit 99.1 to a Form 8-K under Item 2.02. The company noted that the information is being furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Vita Coco Company (COCO) reported an insider transaction by a director. On 10/15/2025, the reporting person sold 3,900 shares of common stock at a weighted average price of $38.915 under a Rule 10b5-1 trading plan. Following the sale, the insider directly beneficially owns 619,966 shares.

The filing also lists a non-qualified stock option to buy 27,300 shares at an exercise price of $10.178, fully vested and currently exercisable, with an expiration date of 01/02/2030.

Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported sales of a total of 7,894 shares of common stock on 10/07/2025 under a Rule 10b5-1 trading plan at weighted average prices in the range of approximately $42.51–$42.91. After the transactions the filing reports 287,062 shares beneficially owned directly and 221,131 shares held indirectly through family trusts. The filing also discloses outstanding non-qualified stock options exercisable for 1,099,460 shares in aggregate, with several option grants fully vested and others vesting in scheduled installments through 2035. The sales were effected pursuant to a pre-established plan and the form was signed by an attorney-in-fact on behalf of the reporting person.

Vita Coco Company, Inc. (COCO) reported insider sales by Martin Roper executed under a Rule 10b5-1 trading plan. The filing shows multiple dispositions of 5,000 shares on 10/03/2025 and 10/06/2025, with reported weighted-average prices around $42.6–$42.9. After the reported sales, Mr. Roper directly beneficially owned 293,897 shares and held indirect interests through family trusts and related parties; several family trusts show remaining indirect holdings in the low- to mid-200,000s.

The form also lists fully vested and exercisable non-qualified stock options and other option grants: a large exercisable option for 579,670 shares at an exercise price of $10.178, plus additional option tranches totaling several hundred thousand shares with exercise prices from $10.178 to $32.78 and various vesting/expiration dates through 2035. The sales were made pursuant to a 10b5-1 plan; the filer offered to provide transaction-level price details on request.

Martin Roper, listed as Director and Chief Executive Officer of Vita Coco Company, Inc. (COCO), reported multiple sales of company common stock under a Rule 10b5-1 trading plan executed on 10/01/2025 and 10/02/2025. The filings show repeated disposals of 5,000-share blocks at weighted average prices in the low $42 range (reported ranges between $41.79 and $42.66). Following the reported 10/01 sale the filing shows 303,897 shares beneficially owned directly; following the 10/02 sale that direct ownership is shown as 298,897. The Form 4 also discloses multiple indirect holdings by related family trusts and a spouse, and reports several non-qualified stock options with exercise prices from $10.178 to $32.78, some fully vested and currently exercisable and others subject to multi-year vesting schedules.

Insider transactions by Vita Coco Company, Inc. (COCO) show the chief operating officer engaged in a planned sale of 3,173 shares of common stock under a Rule 10b5-1 trading plan at $42.50 per share, which reduced his direct holdings from 79,300 to 76,127 shares. The filing also reports the grant and continued ownership of multiple non-qualified stock options with exercise prices ranging from $10.178 to $33.36, some fully vested and exercisable and others subject to multi-year vesting schedules. The disclosure records routine option grants and an executed plan-based sale, providing transparency about executive equity and compensation.

Verlinvest Beverages SA reported beneficial ownership of 4,097,161 shares of The Vita Coco Company, Inc. (ticker COCO), representing 7.2% of the company's outstanding common stock based on 56,822,981 shares outstanding as of July 28, 2025. The filing is a Schedule 13G/A under the Securities Exchange Act and shows Verlinvest holds sole voting and dispositive power over all reported shares. The report lists Verlinvest's address in Ixelles, Belgium, and cites the issuer's principal executive office in New York. No shared ownership, group affiliations, or parties on whose behalf shares are held are disclosed.

Insider sales by Vita Coco CEO and related trusts. Martin Roper reported multiple Rule 10b5-1 sales of common stock on September 24-25, 2025, disposing of blocks of 5,000 and 400 shares at weighted average prices in the ~$40.00–$41.67 range. After these transactions the reporting person directly held 319,297 shares. Related family trusts and spouses show indirect holdings ranging from 252,515 to 253,931 shares, and an additional 61,200 shares are held by a spouse. The filing also discloses large outstanding stock option positions fully exercisable or vesting across 2022–2026, totaling several hundred thousand underlying shares.

Martin Roper, CEO and Director of Vita Coco Company, Inc. (COCO), reported open-market sales of common stock executed under a Rule 10b5-1 trading plan on September 22 and 23, 2025. The filing shows two sales by the reporting person of 5,000 shares on 09/22/2025 and 5,000 shares on 09/23/2025 at weighted-average prices in the ~$40.14–$40.52 range, leaving 324,297 shares held directly after the 09/23 sale. The form also discloses multiple indirect holdings through family trusts and a spouse, and a total of 1,099,460 outstanding stock options across several grant dates and exercise prices, including fully vested options exercisable now.